- Home
- PRQR vs GALT Comparison
PRQR vs GALT Comparison
Compare PRQR & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- GALT
- Stock Information
- Founded
- PRQR 2012
- GALT 2000
- Country
- PRQR Netherlands
- GALT United States
- Employees
- PRQR N/A
- GALT N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- GALT Health Care
- Exchange
- PRQR Nasdaq
- GALT Nasdaq
- Market Cap
- PRQR 232.8M
- GALT 232.3M
- IPO Year
- PRQR 2014
- GALT N/A
- Fundamental
- Price
- PRQR $2.15
- GALT $4.65
- Analyst Decision
- PRQR Strong Buy
- GALT Strong Buy
- Analyst Count
- PRQR 8
- GALT 3
- Target Price
- PRQR $8.88
- GALT $6.00
- AVG Volume (30 Days)
- PRQR 368.1K
- GALT 348.2K
- Earning Date
- PRQR 11-06-2025
- GALT 11-12-2025
- Dividend Yield
- PRQR N/A
- GALT N/A
- EPS Growth
- PRQR N/A
- GALT N/A
- EPS
- PRQR N/A
- GALT N/A
- Revenue
- PRQR $20,129,184.00
- GALT N/A
- Revenue This Year
- PRQR N/A
- GALT N/A
- Revenue Next Year
- PRQR N/A
- GALT N/A
- P/E Ratio
- PRQR N/A
- GALT N/A
- Revenue Growth
- PRQR 8.65
- GALT N/A
- 52 Week Low
- PRQR $1.07
- GALT $0.73
- 52 Week High
- PRQR $4.62
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- PRQR 49.40
- GALT 54.64
- Support Level
- PRQR $1.91
- GALT $4.35
- Resistance Level
- PRQR $2.50
- GALT $6.55
- Average True Range (ATR)
- PRQR 0.16
- GALT 0.46
- MACD
- PRQR -0.03
- GALT -0.06
- Stochastic Oscillator
- PRQR 44.07
- GALT 21.90
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.